A Phase II Trial of SOM230(PasireotideLAR) and Topotecan in Patients With Relapsed or Refractory Small Cell Lung Cancer

Inclusion Criteria

Inclusion criteria

1. Histologically documented SCLC failed one chemotherapy with documentation of relapse
or progressive disease.

2. Measurable or evaluable disease by CT scan. If evaluable disease or measurable
disease has been previously treated, this must show signs of tumor progression by CT.

3. Karnofsky performance status of 80, Age ≥ 18 years and life expectancy of ≥12 weeks

4. Minimum of four weeks since any major surgery, completion of radiation or
chemotherapy

5. ANC ≥ 1.5 x 109/L, Platelets ≥ 100 x 109/L, Hgb > 9 g/dL.

6. Serum bilirubin ≤ 2 x upper limit of normal (ULN), and serum transaminases activity ≤
3 x ULN, with the exception of serum transaminases (< 5 x ULN) if the patient has
liver metastases. Serum creatinine ≤ 1.5 x ULN.

7. Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤ 2.5
x ULN. NOTE: If exceeded, the patient can only be included after initiation of
appropriate lipid lowering medication.

8. Women of childbearing potential must have a negative serum pregnancy test within 14
days of the administration of the first study treatment. Women must not be
lactating.

9. Signed informed consent to participate in the study must be obtained from patients
after they have been fully informed of the nature and potential risks by the
investigator (or his/her designee) with the aid of written information.

Exclusion criteria

1. Prior topotecan or prior octreotide therapy.

2. Chronic treatment with systemic steroids or another immunosuppressive agent.

3. Patients should not receive immunization with attenuated live vaccines during study
period or within 1 week of study entry.

4. Uncontrolled brain or leptomeningeal metastases.

5. Patients with prior or concurrent malignancy except for the following: adequately
treated basal cell or squamous cell skin cancer, or other cancer from which the
patient has been disease free for five years.

6. Patients with uncontrolled diabetes mellitus or a fasting plasma glucose > 1.5 ULN..

7. Patients with symptomatic cholelithiasis.

8. Patients who have congestive heart failure, unstable angina, sustained ventricular
tachycardia, ventricular fibrillation, clinically significant bradycardia, advanced
heart block or a history of acute myocardial infarction within the six months
preceding enrollment.

9. Patients who are at high risk for cardiac arrhythmias as defined by any of the
following:

- Baseline QTcF > 450 msec

- History of syncope or family history of idiopathic sudden death or long QT
syndrome

- Sustained or clinically significant cardiac arrhythmias

- Risk factors for Torsades de Pointes such as hypokalemia, hypomagnesemia,
cardiac failure, clinically significant/symptomatic bradycardia, or high-grade
AV block

- Concomitant disease(s) that could prolong QT such as autonomic neuropathy
(caused by diabetes, or Parkinson's disease), HIV, cirrhosis, uncontrolled
hypothyroidism or cardiac failure

- Concomitant medication(s) known to increase the QT interval

10. Patients taking concomitant medications that are at risk of prolonging QT interval.
If patient is to be included in the study, these medications need to be discontinued

11. Patients with the presence of active or suspected acute or chronic uncontrolled
infection or with a history of immunocompromise, including a positive HIV test result

12. None malignant disease that are uncontrolled such as severe impaired lung function.

13. Women who are pregnant or breast feeding, or women/men able to conceive and unwilling
to practice an effective method of birth control. (Women of childbearing potential
must have a negative serum pregnancy test within 14 days prior to administration of
pasireotide). Oral, implantable, or injectable contraceptives may be affected by
cytochrome P450 interactions, and are therefore not considered effective for this
study.

14. Known hypersensitivity to somatostatin analogues or any component of the pasireotide
or octreotide LAR formulation